Reply: Pulsed Field Ablation for Persistent Atrial Fibrillation: Do Electrophysiological Endpoints Predict Clinical Benefit?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F20%3A00008806" target="_blank" >RIV/00023884:_____/20:00008806 - isvavai.cz</a>
Result on the web
<a href="https://pubmed.ncbi.nlm.nih.gov/33334431/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/33334431/</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Reply: Pulsed Field Ablation for Persistent Atrial Fibrillation: Do Electrophysiological Endpoints Predict Clinical Benefit?
Original language description
The trial was supported by the manufacturer of the ablation system, Farapulse Inc. Dr. Reddy has stock in Farapulse; and has served as a consultant to Farapulse, Biosense-Webster, and Boston Scientific. Dr. Neuzil has received grant support from Farapulse. Dr. Anic has received grant support from and has served as consultant to Farapulse. John Mandrola, MD, served as Guest Associate Editor for this paper. Deepak L. Bhatt, MD, MPH, served as Guest Editor-in-Chief for this paper.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů